 Joanna Poczobutt
Concepts (171)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tumor Microenvironment | 7 | 2020 | 369 | 1.440 |
Why?
| | Macrophages, Alveolar | 3 | 2021 | 371 | 1.340 |
Why?
| | Lung Neoplasms | 9 | 2020 | 2184 | 1.130 |
Why?
| | Niemann-Pick Disease, Type A | 1 | 2021 | 6 | 0.910 |
Why?
| | Niemann-Pick Disease, Type B | 1 | 2021 | 6 | 0.910 |
Why?
| | Lysophospholipase | 1 | 2021 | 12 | 0.910 |
Why?
| | Sphingomyelin Phosphodiesterase | 1 | 2021 | 24 | 0.900 |
Why?
| | Carcinoma, Lewis Lung | 2 | 2019 | 13 | 0.820 |
Why?
| | Glycoproteins | 1 | 2021 | 350 | 0.760 |
Why?
| | Macrophages | 3 | 2021 | 1343 | 0.670 |
Why?
| | Pneumonia | 1 | 2021 | 558 | 0.620 |
Why?
| | Arachidonate 5-Lipoxygenase | 1 | 2015 | 52 | 0.610 |
Why?
| | Adenocarcinoma | 3 | 2017 | 804 | 0.560 |
Why?
| | Idiopathic Pulmonary Fibrosis | 1 | 2019 | 379 | 0.540 |
Why?
| | Leukotrienes | 1 | 2013 | 41 | 0.530 |
Why?
| | Eicosanoids | 1 | 2013 | 65 | 0.520 |
Why?
| | Monocytes | 1 | 2016 | 517 | 0.490 |
Why?
| | Cell Transformation, Neoplastic | 2 | 2011 | 346 | 0.440 |
Why?
| | Breast | 1 | 2010 | 142 | 0.400 |
Why?
| | Disease Models, Animal | 7 | 2021 | 3910 | 0.380 |
Why?
| | T-Lymphocytes | 2 | 2017 | 1846 | 0.360 |
Why?
| | Mice | 14 | 2021 | 15641 | 0.360 |
Why?
| | Mice, Knockout | 5 | 2021 | 2893 | 0.350 |
Why?
| | Epithelial Cells | 2 | 2011 | 1032 | 0.330 |
Why?
| | Macrophage Activation | 2 | 2021 | 172 | 0.330 |
Why?
| | Group IV Phospholipases A2 | 2 | 2017 | 71 | 0.300 |
Why?
| | Neoplasm Transplantation | 2 | 2016 | 268 | 0.300 |
Why?
| | Myeloid Cells | 2 | 2019 | 134 | 0.290 |
Why?
| | PPAR gamma | 2 | 2019 | 180 | 0.280 |
Why?
| | Mice, Inbred C57BL | 8 | 2021 | 5249 | 0.270 |
Why?
| | Cell Line, Tumor | 6 | 2019 | 2936 | 0.260 |
Why?
| | Animals | 15 | 2021 | 35394 | 0.250 |
Why?
| | Programmed Cell Death 1 Receptor | 3 | 2020 | 182 | 0.240 |
Why?
| | Muscle, Smooth, Vascular | 2 | 2016 | 482 | 0.240 |
Why?
| | beta-N-Acetylhexosaminidases | 1 | 2021 | 10 | 0.230 |
Why?
| | Th1-Th2 Balance | 1 | 2021 | 11 | 0.230 |
Why?
| | Chitinases | 1 | 2021 | 9 | 0.230 |
Why?
| | CD11 Antigens | 1 | 2021 | 36 | 0.220 |
Why?
| | Cell Size | 1 | 2021 | 88 | 0.220 |
Why?
| | Lectins | 1 | 2021 | 54 | 0.220 |
Why?
| | CD11b Antigen | 1 | 2021 | 71 | 0.220 |
Why?
| | Disease Progression | 4 | 2019 | 2489 | 0.210 |
Why?
| | Cellular Microenvironment | 1 | 2021 | 80 | 0.210 |
Why?
| | Transforming Growth Factor beta1 | 2 | 2019 | 174 | 0.210 |
Why?
| | Culture Media, Conditioned | 3 | 2021 | 97 | 0.190 |
Why?
| | Phagocytosis | 1 | 2021 | 386 | 0.190 |
Why?
| | Eosinophils | 1 | 2021 | 269 | 0.190 |
Why?
| | Breast Neoplasms | 1 | 2010 | 1909 | 0.190 |
Why?
| | Bone Marrow | 2 | 2017 | 287 | 0.180 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2020 | 382 | 0.180 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2019 | 169 | 0.170 |
Why?
| | Transcriptome | 2 | 2021 | 692 | 0.170 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2019 | 154 | 0.170 |
Why?
| | Receptors, Complement | 1 | 2017 | 128 | 0.170 |
Why?
| | Ureteral Obstruction | 1 | 2017 | 57 | 0.170 |
Why?
| | Trans-Activators | 1 | 2020 | 428 | 0.160 |
Why?
| | Adventitia | 1 | 2016 | 37 | 0.160 |
Why?
| | Lung | 2 | 2021 | 3637 | 0.160 |
Why?
| | Sequence Analysis, RNA | 1 | 2019 | 401 | 0.160 |
Why?
| | Kruppel-Like Transcription Factors | 1 | 2016 | 54 | 0.160 |
Why?
| | Immunocompetence | 1 | 2016 | 46 | 0.160 |
Why?
| | B7-H1 Antigen | 1 | 2017 | 132 | 0.150 |
Why?
| | Myocytes, Smooth Muscle | 2 | 2016 | 247 | 0.150 |
Why?
| | Interferon-gamma | 1 | 2019 | 804 | 0.150 |
Why?
| | Gene Expression | 1 | 2021 | 1588 | 0.150 |
Why?
| | Immunohistochemistry | 2 | 2019 | 1831 | 0.140 |
Why?
| | Cell Proliferation | 5 | 2019 | 2404 | 0.140 |
Why?
| | Nuclear Proteins | 1 | 2020 | 649 | 0.140 |
Why?
| | Neutrophils | 1 | 2021 | 1324 | 0.140 |
Why?
| | Complement Activation | 1 | 2017 | 333 | 0.140 |
Why?
| | Chemokines | 1 | 2016 | 240 | 0.140 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2015 | 366 | 0.140 |
Why?
| | Carcinogenesis | 1 | 2016 | 152 | 0.140 |
Why?
| | Neointima | 1 | 2014 | 13 | 0.140 |
Why?
| | Neoplasm Invasiveness | 1 | 2015 | 454 | 0.140 |
Why?
| | Kidney Diseases | 1 | 2017 | 396 | 0.130 |
Why?
| | Paracrine Communication | 1 | 2014 | 61 | 0.130 |
Why?
| | Vascular System Injuries | 1 | 2014 | 56 | 0.130 |
Why?
| | Immunotherapy | 1 | 2017 | 462 | 0.130 |
Why?
| | Metabolic Networks and Pathways | 1 | 2013 | 188 | 0.120 |
Why?
| | Xenograft Model Antitumor Assays | 2 | 2017 | 788 | 0.120 |
Why?
| | Extracellular Matrix | 1 | 2016 | 421 | 0.120 |
Why?
| | Gene Deletion | 1 | 2013 | 390 | 0.120 |
Why?
| | Lipid Metabolism | 1 | 2016 | 538 | 0.120 |
Why?
| | Flow Cytometry | 1 | 2015 | 1184 | 0.110 |
Why?
| | Stem Cells | 1 | 2016 | 558 | 0.110 |
Why?
| | Coculture Techniques | 3 | 2021 | 212 | 0.110 |
Why?
| | Mammary Glands, Human | 1 | 2011 | 77 | 0.110 |
Why?
| | Transforming Growth Factor beta | 1 | 2014 | 468 | 0.110 |
Why?
| | Colony-Forming Units Assay | 1 | 2010 | 104 | 0.110 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2017 | 1074 | 0.110 |
Why?
| | Cytoplasm | 1 | 2011 | 307 | 0.110 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2019 | 978 | 0.110 |
Why?
| | Cells, Cultured | 3 | 2021 | 4429 | 0.100 |
Why?
| | Hypertension, Pulmonary | 1 | 2021 | 1669 | 0.100 |
Why?
| | Green Fluorescent Proteins | 1 | 2011 | 428 | 0.100 |
Why?
| | MAP Kinase Kinase 2 | 1 | 2009 | 29 | 0.100 |
Why?
| | Humans | 11 | 2021 | 113846 | 0.100 |
Why?
| | MAP Kinase Kinase 1 | 1 | 2009 | 72 | 0.100 |
Why?
| | Cell Communication | 1 | 2010 | 284 | 0.090 |
Why?
| | Gene Expression Profiling | 1 | 2016 | 1640 | 0.090 |
Why?
| | Metabolomics | 1 | 2013 | 532 | 0.090 |
Why?
| | Mice, Nude | 1 | 2010 | 700 | 0.090 |
Why?
| | Recombinant Fusion Proteins | 1 | 2011 | 694 | 0.090 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 909 | 0.090 |
Why?
| | Carcinoma | 1 | 2009 | 212 | 0.090 |
Why?
| | MAP Kinase Signaling System | 1 | 2009 | 320 | 0.090 |
Why?
| | Signal Transduction | 3 | 2019 | 4923 | 0.090 |
Why?
| | Prognosis | 1 | 2016 | 3544 | 0.080 |
Why?
| | Blotting, Western | 1 | 2010 | 1316 | 0.080 |
Why?
| | Female | 5 | 2021 | 63035 | 0.080 |
Why?
| | Proto-Oncogene Proteins | 1 | 2011 | 716 | 0.080 |
Why?
| | Peptide Fragments | 1 | 2011 | 740 | 0.080 |
Why?
| | Male | 6 | 2021 | 60993 | 0.080 |
Why?
| | Thyroid Neoplasms | 1 | 2009 | 249 | 0.080 |
Why?
| | Phenotype | 2 | 2014 | 3050 | 0.080 |
Why?
| | Cytokines | 2 | 2014 | 1981 | 0.080 |
Why?
| | Mice, Transgenic | 3 | 2017 | 2161 | 0.070 |
Why?
| | Mutation | 2 | 2019 | 3447 | 0.070 |
Why?
| | DNA-Binding Proteins | 1 | 2011 | 1460 | 0.070 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2009 | 1210 | 0.060 |
Why?
| | Transcription Factors | 1 | 2011 | 1643 | 0.060 |
Why?
| | Inflammation | 1 | 2013 | 2451 | 0.060 |
Why?
| | Cellular Reprogramming | 1 | 2021 | 91 | 0.050 |
Why?
| | Suppressor of Cytokine Signaling 1 Protein | 1 | 2019 | 13 | 0.050 |
Why?
| | Chemokine CXCL9 | 1 | 2019 | 22 | 0.050 |
Why?
| | Receptors, Transforming Growth Factor beta | 1 | 2019 | 58 | 0.050 |
Why?
| | Gene Silencing | 1 | 2019 | 183 | 0.050 |
Why?
| | Cattle | 1 | 2021 | 980 | 0.050 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2019 | 241 | 0.040 |
Why?
| | Antibodies, Blocking | 1 | 2017 | 36 | 0.040 |
Why?
| | Metabolome | 1 | 2021 | 296 | 0.040 |
Why?
| | Complement C3d | 1 | 2017 | 68 | 0.040 |
Why?
| | Complement C3 | 1 | 2017 | 199 | 0.040 |
Why?
| | Immunoglobulin M | 1 | 2017 | 239 | 0.040 |
Why?
| | Fibroblasts | 1 | 2021 | 906 | 0.040 |
Why?
| | Molecular Targeted Therapy | 1 | 2019 | 380 | 0.040 |
Why?
| | Fibrosis | 1 | 2017 | 425 | 0.040 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2017 | 202 | 0.040 |
Why?
| | Macrophage Colony-Stimulating Factor | 1 | 2014 | 21 | 0.030 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2014 | 314 | 0.030 |
Why?
| | Femoral Artery | 1 | 2014 | 163 | 0.030 |
Why?
| | Biomarkers, Tumor | 1 | 2019 | 1045 | 0.030 |
Why?
| | Nuclear Export Signals | 1 | 2011 | 5 | 0.030 |
Why?
| | Nuclear Localization Signals | 1 | 2011 | 17 | 0.030 |
Why?
| | RNA Interference | 1 | 2014 | 515 | 0.030 |
Why?
| | Peptide Mapping | 1 | 2011 | 73 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-ets | 1 | 2011 | 50 | 0.030 |
Why?
| | Transfection | 1 | 2014 | 997 | 0.030 |
Why?
| | Amino Acid Motifs | 1 | 2011 | 214 | 0.030 |
Why?
| | Fluorescent Antibody Technique | 1 | 2011 | 441 | 0.030 |
Why?
| | Antibodies, Monoclonal | 1 | 2017 | 1302 | 0.030 |
Why?
| | Amino Acid Substitution | 1 | 2011 | 309 | 0.030 |
Why?
| | Thiazolidinediones | 1 | 2011 | 161 | 0.030 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2011 | 405 | 0.030 |
Why?
| | Butadienes | 1 | 2009 | 38 | 0.020 |
Why?
| | Protein Transport | 1 | 2011 | 456 | 0.020 |
Why?
| | Drug Screening Assays, Antitumor | 1 | 2009 | 197 | 0.020 |
Why?
| | Nitriles | 1 | 2009 | 163 | 0.020 |
Why?
| | Benzamides | 1 | 2009 | 186 | 0.020 |
Why?
| | Protein Structure, Tertiary | 1 | 2011 | 906 | 0.020 |
Why?
| | Cell Differentiation | 1 | 2016 | 1842 | 0.020 |
Why?
| | Amino Acid Sequence | 1 | 2011 | 2229 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 2011 | 3118 | 0.020 |
Why?
| | Enzyme Inhibitors | 1 | 2009 | 945 | 0.020 |
Why?
| | Pregnancy | 1 | 2016 | 5290 | 0.020 |
Why?
| | Cell Line | 1 | 2011 | 3016 | 0.020 |
Why?
| | Rats | 1 | 2014 | 6387 | 0.020 |
Why?
| | Hypoglycemic Agents | 1 | 2011 | 1044 | 0.020 |
Why?
| | Biomarkers | 1 | 2014 | 3501 | 0.020 |
Why?
| | Time Factors | 1 | 2014 | 7060 | 0.010 |
Why?
|
|
Poczobutt's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|